What question did this study set out to answer?

The aim is to investigate the role of diaporine in enhancing the effects of anticancer drugs on liver cancer cells.

February 11, 2026Journal of Personalized Medicine0 citationsOpen Access

Correction: Tian et al. Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells. J. Pers. Med. 2022, 12, 1318

Q: What is the clinical evidence from this study?

Study design: Other. Population: Liver cancer cells (in vitro). Intervention: Diaporine combined with Oxaliplatin and Doxorubicin vs. Oxaliplatin and Doxorubicin alone. Primary outcome: Anticancer effects on liver cancer cells.

STShiliu Tian RSRui SuUniversity of California, Berkeley KWKe WuUCLA Jonsson Comprehensive Cancer Center

Key Result

Diaporine potentiates the anticancer effects of Oxaliplatin and Doxorubicin on liver cancer cells in vitro, but exact quantitative results were not provided.

Key Points

The aim is to investigate the role of diaporine in enhancing the effects of anticancer drugs on liver cancer cells.
In vitro experiments on liver cancer cell lines
Assessment of cellular response to drug treatment
Analysis of drug interactions
Diaporine significantly increases the effectiveness of oxaliplatin
Doxorubicin's anticancer effects are also enhanced by diaporine
Combined treatments show more substantial tumor cell death than individual drugs

PICO

Population

Liver cancer cells (in vitro)

Intervention / Comparator

Diaporine combined with Oxaliplatin and Doxorubicin vs Oxaliplatin and Doxorubicin alone

Primary Outcome

Anticancer effects on liver cancer cells

Limitations

No quantitative clinical trial data provided, study focused on in vitro experiments
No details on sample size, randomization, dosing, and clinical outcomes
Findings are preclinical and may not translate directly to patient outcomes

Abstract

In the original publication ...

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper